Anna Saborowski, Katharina Wolff, Steffi Spielberg, Benedikt Beer, Björn Hartleben, Zulrahman Erlangga, Diana Becker, Lukas E. Dow, Silke Marhenke, Norman Woller, Kristian Unger, Peter Schirmacher, Michael P. Manns, Jens U. Marquardt, Arndt Vogel, Michael Saborowski – 5 February 2019 – The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5‐year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies.

Felice Ho‐Ching Tsang, Cheuk‐Ting Law, Tsz‐Ching Chloe Tang, Carol Lai‐Hung Cheng, Don Wai‐Ching Chin, Wing‐Sum Vincy Tam, Lai Wei, Carmen Chak‐Lui Wong, Irene Oi‐Lin Ng, Chun‐Ming Wong – 5 February 2019 – Hepatocellular carcinoma (HCC) cells exploit an aberrant transcriptional program to sustain their infinite growth and progression. Emerging evidence indicates that the continuous and robust transcription of oncogenes in cancer cells is often driven by super‐enhancers (SEs).

Peter Jepsen, Matthew J. Grainge – 5 February 2019

Akiko Matsuda, Kaori Ishiguro, Irene K. Yan, Tushar Patel – 4 February 2019 – Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. Although HCC can respond to immune checkpoint inhibitors, such as monoclonal antibodies against programmed death 1 (PD‐1), many patients fail to respond or develop secondary resistance. Activation of Wnt/β‐catenin signaling can contribute to immune evasion. Mutations in β‐catenin are among the most frequent mutations associated with HCC.

Simon Musyoka Mwangi, Ge Li, Lan Ye, Yunshan Liu, Francois Reichardt, Samantha M. Yeligar, C. Michael Hart, Mark J. Czaja, Shanthi Srinivasan – 4 February 2019 – Glial cell line–derived neurotrophic factor (GDNF) is a protein that is required for the development and survival of enteric, sympathetic, and catecholaminergic neurons. We previously reported that GDNF is protective against high fat diet (HFD)‐induced hepatic steatosis in mice through suppression of hepatic expression of peroxisome proliferator activated receptor‐γ and genes encoding enzymes involved in de novo lipogenesis.

Thomas G. Cotter, Sonali Paul, Burhaneddin Sandıkçı, Thomas Couri, Adam S. Bodzin, Ester C. Little, Vinay Sundaram, Michael Charlton – 4 February 2019 – Highly effective direct‐acting antiviral (DAA) therapy has transformed outcomes of liver transplantation in hepatitis C virus (HCV) patients. We examined longer‐term outcomes in HCV‐positive recipients in the DAA era and analyzed the Scientific Registry of Transplant Recipients for primary adult, single‐organ, nonfulminant liver transplant recipients in the United States from January 1, 2008 to June 30, 2018.

Uta Herden, Enke Grabhorn, René Santer, Jun Li, Silvio Nadalin, Xavier Rogiers, Marcus N. Scherer, Felix Braun, Jan Beime, Henning Lenhartz, Ania C. Muntau, Lutz Fischer – 3 February 2019 – Liver transplantation (LT) has been shown to be a feasible treatment in patients with severe forms of maple syrup urine disease (MSUD). Because of a sufficient extrahepatic enzyme activity in non‐MSUD individuals, the organ of MSUD patients can be used as a domino graft.

Michael Pimienta, Alexander Beletsky, Ekihiro Seki – 1 February 2019

1 February 2019

Marlyn J. Mayo, Paul J. Pockros, David Jones, Christopher L. Bowlus, Cynthia Levy, Imran Patanwala, Bruce Bacon, Velimir Luketic, Raj Vuppalanchi, Sharon Medendorp, Alejandro Dorenbaum, Ciara Kennedy, Patricia Novak, Joan Gu, George Apostol, Gideon M. Hirschfield – 1 February 2019 – Primary biliary cholangitis (PBC) is typically associated with elevated serum bile acid levels and pruritus, but pruritus is often refractory to treatment with existing therapies.